• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Science & Medicine / HPV Science / Behind the Scenes: The Evolution of an HPV Industry

Behind the Scenes: The Evolution of an HPV Industry

April 5, 2011 By Jonathan Leave a Comment

 

By Norma Erickson, President of SaneVax Inc.

April 5, 2011

The first papillomavirus was discovered in the 1930’s by Dr. Richard E. Shope. It was the cottontail rabbit papillomavirus, or the Shope papillomavirus, which occurred in warts that frequently developed into cancerous tumors1. Dr. Shope was able to isolate the virus, inject it into other rabbits and produce similar cancerous tumors, thus providing evidence (an animal model) of cancer in mammals apparently caused by a virus.

Although the viral nature of human warts had been noted as early as 1907, little research was done regarding human papillomavirus (HPV) until the development of DNA sequencing technology in the mid 1970’s. Dr. Harald zur Hausen suspected human papillomavirus may exhibit the same progression (warts to cancer) in people that Shope papillomavirus did in rabbits.

After ten years of searching, Dr. zur Hausen discovered HPV 16 and 18 DNA in human invasive cervical cancers. Using the virus DNA retrieved from cervical cancers, he was able to successfully clone HPV 16 and HPV 18 in 19842.

The successful cloning of HPV 16/18 led to research projects aimed at producing the HPV antigens and finding a way to elicit antibodies to them in animals first, and ultimately humans. Research conducted at the University of Queensland (Australia), Georgetown University, the National Cancer Institute, and the University of Rochester culminated in patents filed between 1991 and 1993 by each organization.

Between 1995 and 1998, various pharmaceutical companies obtained rights, or partial rights to these patents. Much of the intellectual property (IP) patented involved knowledge and techniques that overlapped each other with various pharmaceutical companies having the rights to only part of the technology necessary for them to do anything with it.

The United States patent system works on a first to invent basis rather than a first to file system. A patent interference claim arises when two parties have patented similar information. It is basically a priority contest to determine who has the ultimate right to license the patent to other parties. Six two-way patent interference claims between the four inventors were declared by the U.S. Patent and Trademark Office in 2001.

Not knowing which inventing organization would ultimately win the patent interference battle, many pharmaceutical companies who had purchased partial or exclusive rights from one of the four organizations gave up the battle. Merck and GlaxoSmithKline each ended up with rights to utilize the patented information from different organizations.

Given the uncertainty surrounding the ownership of the patented technology enabling the production of HPV vaccines and the possibility that each could block the other’s production, they decided to enter into a cross-license agreement with each other in February 2005. Their market position was now secured in the United States, Europe, and 32 other countries belonging to the Organization for Economic Co-operation and Development3.

In a 2001 article, titled Vaccines: The Next Step to Cervical Cancer Prevention, Journal of the National Cancer Institute, Mark Schiffman, MD, National Cancer Institute Division of Cancer Epidemiology and Genetics responded to this question:

“Once we know how to use information from human papillomavirus tests to effectively test and treat women for cervical abnormalities, what is next?”

“Vaccines,” said Mark Schiffman, M.D., of the National Cancer Institute’s Division of Cancer Epidemiology and Genetics. “[Cervical cancer] should be a vaccine-preventable cancer.”

Read Full Article…

Related

Filed Under: HPV Science, Human Papillomavirus Research, Pharmaceutical Companies, SANE Vax Press Releases Tagged With: Cervical Cancer HPV, DNA sequencing, HPV research, pharmaceutical companies, Sane Vax

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Norway: Force vaccinated with Gardasil

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

uk hpv

UK HPV Vaccine Programme Errors. Aluminum Toxin

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in